315 related articles for article (PubMed ID: 10370782)
1. Paclitaxel by 24-hour infusion with doxorubicin by 48-hour infusion as initial therapy for metastatic breast cancer: phase I results.
Holmes FA; Valero V; Walters RS; Theriault RL; Booser DJ; Gibbs H; Fraschini G; Buzdar AU; Willey J; Frye D; Asmar L; Hortobagyi GN
Ann Oncol; 1999 Apr; 10(4):403-11. PubMed ID: 10370782
[TBL] [Abstract][Full Text] [Related]
2. Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumor efficacy and cardiac effects in a dose-finding and sequence-finding study.
Gianni L; Munzone E; Capri G; Fulfaro F; Tarenzi E; Villani F; Spreafico C; Laffranchi A; Caraceni A; Martini C
J Clin Oncol; 1995 Nov; 13(11):2688-99. PubMed ID: 7595726
[TBL] [Abstract][Full Text] [Related]
3. Update: the M.D. Anderson Cancer Center experience with paclitaxel in the management of breast carcinoma.
Holmes FA
Semin Oncol; 1995 Aug; 22(4 Suppl 8):9-15. PubMed ID: 7543702
[TBL] [Abstract][Full Text] [Related]
4. Paclitaxel combined with weekly high-dose 5-fluorouracil/folinic acid and cisplatin in the treatment of advanced breast cancer.
Klaassen U; Wilke H; Seeber S
Semin Oncol; 1996 Oct; 23(5 Suppl 11):32-7. PubMed ID: 8893897
[TBL] [Abstract][Full Text] [Related]
5. A phase I/II study of sequential doxorubicin and paclitaxel in the treatment of advanced breast cancer.
Amadori D; Frassineti GL; Zoli W; Milandri C; Tienghi A; Ravaioli A; Gentile A; Salzano E
Semin Oncol; 1996 Oct; 23(5 Suppl 11):16-22. PubMed ID: 8893894
[TBL] [Abstract][Full Text] [Related]
6. Phase II trial of doxorubicin/docetaxel/cyclophosphamide for locally advanced and metastatic breast cancer: results from NSABP trial BP-58.
Smith RE; Anderson SJ; Brown A; Scholnik AP; Desai AM; Kardinal CG; Lembersky BC; Mamounas EP
Clin Breast Cancer; 2002 Dec; 3(5):333-40. PubMed ID: 12533263
[TBL] [Abstract][Full Text] [Related]
7. Treatment of metastatic breast cancer with paclitaxel and doxorubicin.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BW; Ejlertsen B
Semin Oncol; 1995 Dec; 22(6 Suppl 15):13-7. PubMed ID: 8643964
[TBL] [Abstract][Full Text] [Related]
8. Paclitaxel and doxorubicin, a highly active combination in the treatment of metastatic breast cancer.
Dombernowsky P; Gehl J; Boesgaard M; Jensen TP; Jensen BV
Semin Oncol; 1996 Feb; 23(1 Suppl 1):13-8. PubMed ID: 8629030
[TBL] [Abstract][Full Text] [Related]
9. A phase II study of doxorubicin/paclitaxel plus G-CSF for metastatic breast cancer.
Schwartsmann G; Mans DR; Menke CH; Xavier N; Caleffi M; Ferreira Filho AF; Schunemann H; Kalakun L; Koya R; Pohlman P; Venegas LF
Oncology (Williston Park); 1997 Apr; 11(4 Suppl 3):24-9. PubMed ID: 9144687
[TBL] [Abstract][Full Text] [Related]
10. Doxorubicin and paclitaxel in advanced breast carcinoma: importance of prior adjuvant anthracycline therapy.
Lluch A; Ojeda B; Colomer R; Barnadas A; Massuti B; Casado A; Angeles C; Maroto P
Cancer; 2000 Dec; 89(11):2169-75. PubMed ID: 11147586
[TBL] [Abstract][Full Text] [Related]
11. Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A; Guarneri V; Landucci E; Orlandini C; Rondini M; Salvadori B; Ricci S; Conte PF
Clin Breast Cancer; 2002 Dec; 3(5):346-52. PubMed ID: 12533265
[TBL] [Abstract][Full Text] [Related]
12. Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.
Gianni L; Munzone E; Capri G; Villani F; Spreafico C; Tarenzi E; Fulfaro F; Caraceni A; Martini C; Laffranchi A
J Natl Cancer Inst; 1995 Aug; 87(15):1169-75. PubMed ID: 7674322
[TBL] [Abstract][Full Text] [Related]
13. Paclitaxel in the treatment of metastatic breast cancer: M.D. Anderson Cancer Center experience.
Buzdar AU; Holmes FA; Hortobagyi GN
Semin Oncol; 1995 Jun; 22(3 Suppl 6):101-4. PubMed ID: 7541151
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy with Taxol (paclitaxel) in metastatic breast cancer.
Holmes FA
Ann Oncol; 1994; 5 Suppl 6():S23-7. PubMed ID: 7865429
[TBL] [Abstract][Full Text] [Related]
15. Paclitaxel in doxorubicin-refractory or mitoxantrone-refractory breast cancer: a phase I/II trial of 96-hour infusion.
Wilson WH; Berg SL; Bryant G; Wittes RE; Bates S; Fojo A; Steinberg SM; Goldspiel BR; Herdt J; O'Shaughnessy J
J Clin Oncol; 1994 Aug; 12(8):1621-9. PubMed ID: 7913721
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel and epirubicin as first-line therapy in patients with metastatic breast cancer.
Lück HJ; Thomssen C; du Bois A; Untch M; Lisboa B; Köhler G; Diergarten K
Semin Oncol; 1997 Oct; 24(5 Suppl 17):S17-35-S17-39. PubMed ID: 9374090
[TBL] [Abstract][Full Text] [Related]
17. Phase II trial of paclitaxel by 3-hour infusion as initial and salvage chemotherapy for metastatic breast cancer.
Seidman AD; Tiersten A; Hudis C; Gollub M; Barrett S; Yao TJ; Lepore J; Gilewski T; Currie V; Crown J
J Clin Oncol; 1995 Oct; 13(10):2575-81. PubMed ID: 7595709
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial of escalating doses of paclitaxel plus doxorubicin and dexrazoxane in patients with advanced breast cancer.
Sparano JA; Speyer J; Gradishar WJ; Liebes L; Sridhara R; Mendoza S; Fry D; Egorin MJ
J Clin Oncol; 1999 Mar; 17(3):880-6. PubMed ID: 10071279
[TBL] [Abstract][Full Text] [Related]
19. A detailed evaluation of cardiac toxicity: a phase II study of doxorubicin and one- or three-hour-infusion paclitaxel in patients with metastatic breast cancer.
Giordano SH; Booser DJ; Murray JL; Ibrahim NK; Rahman ZU; Valero V; Theriault RL; Rosales MF; Rivera E; Frye D; Ewer M; Ordonez NG; Buzdar AU; Hortobagyi GN
Clin Cancer Res; 2002 Nov; 8(11):3360-8. PubMed ID: 12429622
[TBL] [Abstract][Full Text] [Related]
20. Phase I/II study of 72-hour infusional paclitaxel and doxorubicin with granulocyte colony-stimulating factor in patients with metastatic breast cancer.
Fisherman JS; Cowan KH; Noone M; Denicoff A; Berg S; Poplack D; Balis F; Venzon D; McCabe M; Goldspiel B; Chow C; Ognibene FP; O'Shaughnessy J
J Clin Oncol; 1996 Mar; 14(3):774-82. PubMed ID: 8622023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
